TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Preparation for call duties
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Improved intercourse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: myocardial ischaemia during balloon inflation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Overall rate of any grade adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Overall rate of grade 3-4 adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of delayed-union
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean duration of reflux episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: total acid exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: incidence of tube displacement
Endpoint domain: Adverse events/effects
Primary endpoint: SpO2 and PaO2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean score increase on pre- and posttests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Defecation urgency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rate of secondary illness
Endpoint domain: Adverse events/effects
Primary endpoint: Absolute heme-iron absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Activity of antithrombin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of ephedrine treatments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total dose of ephedrine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of severe vomiting
Endpoint domain: Adverse events/effects
Primary endpoint: subjective pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: surgeons' satisfaction scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of reflux in upper thigh veins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Reflux times in common femoral vein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: LDL-C concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean LDL particle size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: LDL apoB100 fractional catabolic rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: unfavorable HRQOL
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: interventional complication rates
Endpoint domain: Adverse events/effects
Primary endpoint: hemorrhage rates
Endpoint domain: Adverse events/effects
Primary endpoint: Mean temperature increase from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: worsening heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: death or worsening heart failure
Endpoint domain: Mortality/survival
Primary endpoint: LH surge detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: mean area under the curve for LH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mean plasma ROS increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean 8-isoprostane increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: weight or body composition changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of dislocation
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of women who made a decision
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Improvement of clinical symptoms of laryngopharynx
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient's perception of the postoperative period
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: mean central-laboratory K+ level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in HAM-D
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in EPDS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically significant improvements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electing for intensive intervention
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: eGPx concentration in GCF and serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Port implantation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Port related complaints postoperatively
Endpoint domain: Adverse events/effects
Primary endpoint: Fall in PSA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median supplemental lidocaine requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for analgesia in the first 24 h after operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to receive analgesia after operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CGI-TD mean score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximal pain assessed with numerical rating scale (NRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Net uptake of amino acids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle net protein breakdown
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cellular Tyndall
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrement in utility associated with anxiety/depression
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Decrement in utility associated with pain/discomfort
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of hypotensive episodes per patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to onset of first hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Postoperative OPS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: success rate in controlling post-partum hemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: KOOS-Quality of Life (KOSS-QOL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Weekly drop-seizure rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Serious pulmonary toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in urinary hippurate and aromatic amino acids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Increase in plasma branched chain amino acids, alanine, glutamine, and glutamate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Parenteral opioid use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body mass index z-scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Treatment failure (defined as >2 consecutive BG >240 mg/dL or a mean daily BG >240 mg/dL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Frequency of BG <70 mg/dL
Endpoint domain: Adverse events/effects
Primary endpoint: Daily serum bilirubin reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Days for normalizing serum bilirubin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Forearm vascular resistance responses to adrenergic stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Healing scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Development of small gastroduodenal lesions
Endpoint domain: Adverse events/effects
Primary endpoint: glucose metabolic clearance rate (MCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Conversion to neovascular AMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: scar count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: percentage of subjects with SGA of 'almost clear'
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: total acne lesion count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: NNS bursts per min
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NNS events per min
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total oral compressions per min
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heartburn severity area under the curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Clinical success end-point
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Luminal dimension at 3 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Intraluminal scaffold dismantling (ISD) at 3 years
Endpoint domain: Adverse events/effects
Primary endpoint: mean arterial pressure changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: brain activity in the right DLPFC and medial frontal gyrus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: activation change in the left posterior cingulate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction in obsession severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Acute rejection risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Selenium concentrations in plasma and red cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in oral health
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved gingival condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: distance between anterior and posterior lens capsules
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: space‐maintaining capacity during surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of re-intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: mean bleeding score on POD one
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intracellular gemcitabine‐triphosphate accumulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WBC accumulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Reduction in midcycle neutrophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Qs/Qt ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in BCVA from baseline to week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stroke or systemic embolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: severe dry mouth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: needing to sip fluids to swallow food
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: waking up at night to drink
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BP normalization percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 24-hour BP variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: enophthalmos severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: diplopia status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: satisfactory result
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Hematologic toxicity (Grade 3-4 anemia, neutropenia, thrombocytopenia)
Endpoint domain: Adverse events/effects
Primary endpoint: Maximal global systolic tissue velocity (Vmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximal mitral annulus velocity (S'max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 6-minute hall walk distance
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Recovery after 5 years
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Employment or studying status after 5 years
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Reduction of mean initial SI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systemic side effects (nausea and/or dizziness)
Endpoint domain: Adverse events/effects
Primary endpoint: Implicit times of multifocal ERG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraventricular hemorrhage
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of nausea, vomiting, and pruritus
Endpoint domain: Adverse events/effects
Primary endpoint: Low-Density Lipoprotein Cholesterol (LDL-C) reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: TC:HDL ratio reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in sexual function (decrease in SAFTEE sex total score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients seizure-free after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost of the presurgical evaluation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: MIP-1alpha levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Adequate management of blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Adequate management of cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: median number of diagnoses per patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: documentation quality ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emergence of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: treatment success at 90 days post-treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Marinoff dyspareunia scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to relax the PFM after contraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to anti-malarial treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median time to reach t0.25 μg/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0‐60
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Onset of gastric emptying
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Diagnosis of advanced prostate cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of severe hypoxemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total heartburn symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: time to first sensation of heartburn
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Short-term sex work cessation
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Impact on activities
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Relative vaccine efficacy in severe influenza
Endpoint domain: Mortality/survival
Primary endpoint: decrease in mSBI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean decrease in PD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean percentage of bone fill
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disruption of taste
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximal grip strength of the affected hand
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: modified Ashworth spasticity total scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Base Excess (BE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: survival rates of restorations
Endpoint domain: Mortality/survival
Primary endpoint: u-ENaCbeta levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence of second seizure within six months
Endpoint domain: Mortality/survival
Primary endpoint: clinically relevant improvement in RSD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adjuvant treatment costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: total medical costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Surface roughness of restorations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to complete 5-km TT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of total hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Frequency of additional rescue drug administered
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: weakening of IOOA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of satisfactory results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean maternal weight decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean BMI decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean waist circumference decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean change from baseline in HBV DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood pressure variability (SBPV and DBPV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: skin hydration increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: freedom from first progression
Endpoint domain: Mortality/survival
Primary endpoint: Spinal loads
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Probability of allograft rejection at 6 months
Endpoint domain: Mortality/survival
Primary endpoint: Median time to first acute rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Actuarial event-free survival rates at 6 months
Endpoint domain: Mortality/survival
Primary endpoint: tolerability of TAK-044
Endpoint domain: Adverse events/effects
Primary endpoint: Average ST segment depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Extent score assessed by 201Tl-SPECT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Severity score assessed by 201Tl-SPECT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: VT (Tidal Volume)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of ineffective triggering
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of double triggering
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DAS28 (ESR) < 2.6 maintained at 24 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HAQ-DI at six months
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: No evidence of radiographic progression at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean total charges
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean estimated total costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use